Oncology Medical Conversation
By COR2ED Medical Education
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by COR2ED Medical Education
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 71
Description
Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy.
This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com
| Episode | Date |
|---|---|
|
Understanding the needs of different patient populations in colorectal cancer
|
May 15, 2024 |
|
Interpreting real-world evidence in later-line mCRC
|
May 07, 2024 |
|
Cáncer de ovario: dificultades en la fase preanalítica y pruebas de biomarcadores
|
Apr 25, 2024 |
|
Câncer de ovário: Desafios da fase pré-analítica e teste de biomarcadores
|
Apr 25, 2024 |
|
Cáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores
|
Apr 25, 2024 |
|
Câncer de Próstata: Desafios da Fase Pré-Analítica e Teste de Biomarcadores
|
Apr 25, 2024 |
|
Cáncer de pulmón: dificultades en la fase preanalítica y pruebas de biomarcadores
|
Apr 25, 2024 |
|
Câncer de pulmão: Desafios da fase pré-analítica e teste de biomarcadores
|
Apr 25, 2024 |
|
mCRC: Optimising patient outcomes with late-line treatment
|
Mar 28, 2024 |
|
Perseverance pays off – Looking beyond the obvious mutations in NSCLC
|
Mar 28, 2024 |
|
Ovarian cancer: Pre-analytical phase challenges and biomarker testing
|
Feb 23, 2024 |
|
Lung cancer: Pre-analytical phase challenges and biomarker testing
|
Jan 25, 2024 |
|
Treatment optimization in mCRC: third-line and beyond
|
Jan 10, 2024 |
|
Precision oncology: An overview of tumour agnostic therapies
|
Dec 07, 2023 |
|
Prostate Cancer: Pre-Analytical Phase Challenges and Biomarker Testing
|
Dec 06, 2023 |
|
Severe PHH. Part 2 - Learnings from clinical practice
|
Dec 06, 2023 |
|
Managing thrombosis: Part 2 - Cancer and thrombosis
|
Dec 06, 2023 |
|
Advanced HCC: 2nd line treatment and the right time to switch
|
Dec 06, 2023 |
|
Breast cancer: Oral SERDs in ER+ BC. Part 3 - Rare cases & treatment challenges
|
Dec 06, 2023 |
|
Precision oncology: An introduction to molecular testing
|
Dec 06, 2023 |
|
Breast cancer: Oral SERDs in ER+ BC. Part 2 - Treatment selection and beyond
|
Dec 06, 2023 |
|
Gastric and GEJ cancers: Clinical case discussions. Part 2 - metastatic disease
|
Dec 06, 2023 |
|
Gastric and GEJ cancers: Clinical case discussions. Part 1 - non-metastatic disease
|
Dec 06, 2023 |
|
Breast cancer: Oral SERDs in ER+ BC. Part 1 - Efficacy, safety and the treatment landscape
|
Dec 06, 2023 |
|
Prostate cancer: Treatment intensification in mCSPC - The nurse perspective
|
Dec 06, 2023 |
|
Colorectal cancer: Treatment sequencing in advanced mCRC
|
Dec 06, 2023 |
|
Prostate cancer: Which mCSPC patients benefit from early treatment intensification? Case-based discussion
|
Dec 06, 2023 |
|
Prostate cancer: PARP inhibitors. Part 3 - Efficacy and safety of combination therapy
|
Dec 06, 2023 |
|
Advanced HCC: Patients not eligible for IO - What are the treatment options?
|
Dec 06, 2023 |
|
Prostate cancer: PARP inhibitors. Part 2 - Combination therapy; US and EU perspectives
|
Dec 06, 2023 |
|
Prostate cancer: PARP inhibitors. Part 1 - PARPi monotherapy; US and EU perspectives
|
Dec 06, 2023 |
|
Endometrial carcinoma: Systemic therapies. Part 2 - The nurses' perspective
|
Dec 06, 2023 |
|
Endometrial carcinoma: Systemic therapies. Part 1 - The physicians' perspective
|
Dec 06, 2023 |
|
Lower GI cancer: Highlights from ASCO GI 2023 - Part 2
|
Dec 06, 2023 |
|
Upper GI cancer Highlights from ASCO GI 2023 - Part 1
|
Dec 06, 2023 |
|
Sarcoma: Updates from CTOS 2022
|
Dec 06, 2023 |
|
Advanced RCC: Clinical implementation of targeted therapies and immunotherapies
|
Dec 06, 2023 |
|
Neuroendocrine tumours: The role of SSA at progression - To continue or not?
|
Dec 06, 2023 |
|
HCC: Updates from ILCA and ESMO 2022
|
Dec 06, 2023 |
|
Upper GI cancer: Update from ESMO 2022 - Part 2
|
Dec 06, 2023 |
|
Lower GI cancer: Update from ESMO 2022 - Part 1
|
Dec 06, 2023 |
|
Colorectal cancer: Flexible dosing of oral treatments in mCRC
|
Dec 06, 2023 |
|
Sarcoma: Updated bone sarcoma guidelines - Clinical implications
|
Dec 06, 2023 |
|
HCC: The role of immunotherapy beyond advanced HCC
|
Dec 06, 2023 |
|
Prostate cancer: Highlights from ASCO GU, ASCO and EAUN 2022
|
Dec 06, 2023 |
|
Prostate cancer: Shared decision-making in nmCRPC
|
Dec 06, 2023 |
|
Prostate cancer: Timing of ARSI and taxanes in mCSPC
|
Dec 06, 2023 |
|
GI cancer: Management of skin toxicity from multikinase inhibitors
|
Dec 06, 2023 |
|
Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3
|
Dec 06, 2023 |
|
Prostate cancer: Highlights from ASCO GU 2022
|
Dec 06, 2023 |
|
HCC: Key topics discussed at ASCO GI & EASL 2022
|
Dec 06, 2023 |
|
Prostate cancer: PARP inhibitors in prostate cancer
|
Dec 06, 2023 |
|
Cáncer de próstata: Inhibidores de PARP - lo que las enfermeras necesitan saber
|
Dec 06, 2023 |
|
Prostate cancer: PARP inhibitors in prostate cancer - What nurses need to know
|
Dec 06, 2023 |
|
Prostate cancer: Genetic testing and PARP inhibitors in prostate cancer
|
Dec 06, 2023 |
|
Precision oncology: Detection and treatment of TRK fusion-positive lung cancers
|
Dec 06, 2023 |
|
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors
|
Dec 06, 2023 |
|
RCC: Treating advanced RCC - The role of VEGFR-TKIs alone or in combination therapy
|
Dec 06, 2023 |
|
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 3 - Future developments
|
Dec 06, 2023 |
|
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 2 - Immunotherapy
|
Dec 06, 2023 |
|
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 1 - Targeted therapy
|
Dec 06, 2023 |
|
Multiple Myeloma: Choosing the best treatment regimen in patients with relapsed/refractory MM - Part 2
|
Dec 06, 2023 |
|
HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting
|
Dec 06, 2023 |
|
Multiple Myeloma: Choosing the best treatment regimen in newly diagnosed patients - Part 1
|
Dec 06, 2023 |
|
HCC: Highlights from ILCA and ESMO 2021
|
Dec 06, 2023 |
|
Precision oncology: Diagnosis and treatment of TRK fusion-positive GI cancers
|
Dec 06, 2023 |
|
VEGFR-TKIs: Nurse management of adverse events
|
Dec 06, 2023 |
|
Thyroid cancer: Optimising VEGFR-TKIs (MKIs) in differentiated thyroid cancer
|
Dec 06, 2023 |
|
HCC: Highlights from ASCO and WCGIC 2021
|
Dec 06, 2023 |
|
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics
|
Dec 06, 2023 |
|
Prostate cancer: Radiopharmaceuticals. Part 1 - Radium-223
|
Dec 06, 2023 |